{
    "Clinical Trial ID": "NCT00445458",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Neratinib 160 mg + Paclitaxel 80 mg/m\u00b2",
        "  Neratinib 160 mg qd + Paclitaxel 80 mg/m\u00b2 IV on days 1, 8, and 15 of a 28 day cycle.",
        "INTERVENTION 2: ",
        "  Neratinib 240 mg + Paclitaxel 80 mg/m\u00b2",
        "  Neratinib 240 mg qd + Paclitaxel 80 mg/m\u00b2 IV on days 1, 8, and 15 of a 28 day cycle."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Inclusion criteria for both parts of clinical trial:",
        "  Good performance status",
        "  Normal ejection fraction",
        "  Adequate cardiac, kidney, and liver function",
        "  Adequate blood counts",
        "  At least one measurable target lesion",
        "  Negative pregnancy test for female subjects",
        "  Inclusion Criteria for Part 1 Only:",
        "  - Pathologically confirmed solid tumor not curable with available standard therapy",
        "  Inclusion Criteria for Part 2 Only:",
        "  Pathologically confirmed breast cancer",
        "  HER2 positive tumor",
        "  Prior treatment with Herceptin",
        "Exclusion Criteria:",
        "  Exclusion criteria for both parts of clinical trial:",
        "  Major surgery, radiotherapy, chemotherapy or investigational agents within two weeks of treatment day 1",
        "  Subjects with bone or skin as the only site of disease",
        "  Active central nervous system metastases",
        "  Significant cardiac disease or dysfunction",
        "  Significant gastrointestinal disorder",
        "  Inability or unwillingness to swallow HKI-272 capsules",
        "  Prior exposure to HKI-272 or other HER2 targeted agents, except trastuzumab (Part 2 only). Prior lapatinib is permitted in arm B of part 2.",
        "  Treatment with a taxane within 3 months of treatment day 1",
        "  Grade 2 or greater motor or sensory neuropathy",
        "  Pregnant or breast feeding women",
        "  Known hypersensitivity to paclitaxel or Cremophor EL",
        "  Prior treatment with anthracyclines with cumulative dose of >400 mg/m^2",
        "  Any other cancer within 5 years with the exception of contralateral breast cancer, adequately treated cervical carcinoma in situ, or adequately treated basal or squamous cell carcinoma of the skin",
        "  Exclusion Criteria for Part 2 Only:",
        "  - More than 1 (arm A) or 3 (arm B) prior cytotoxic chemotherapy regimen for metastatic disease"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Dose Limiting Toxicity Incidence of Neratinib in Combination With Paclitaxel",
        "  Dose Limiting Toxicity in subjects with solid tumors treated with neratinib, administered daily, in combination with paclitaxel 80 mg/m\u00b2 IV on days 1, 8, and 15 of a 28 day cycle.",
        "  Time frame: From first dose date through day 28",
        "Results 1: ",
        "  Arm/Group Title: Neratinib 160 mg + Paclitaxel 80 mg/m ",
        "  Arm/Group Description: Neratinib 160 mg qd + Paclitaxel 80 mg/m  IV on days 1, 8, and 15 of a 28 day cycle.",
        "  Overall Number of Participants Analyzed: 3",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  0   0.0%",
        "Results 2: ",
        "  Arm/Group Title: Neratinib 240 mg + Paclitaxel 80 mg/m ",
        "  Arm/Group Description: Neratinib 240 mg qd + Paclitaxel 80 mg/m  IV on days 1, 8, and 15 of a 28 day cycle.",
        "  Overall Number of Participants Analyzed: 5",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  0   0.0%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/3 (33.33%)",
        "  Anaemia 0/3 (0.00%)",
        "  Febrile neutropenia 0/3 (0.00%)",
        "  Leukopenia 0/3 (0.00%)",
        "  Sinus tachycardia 1/3 (33.33%)",
        "  Cataract 0/3 (0.00%)",
        "  Abdominal discomfort 1/3 (33.33%)",
        "  Diarrhoea 1/3 (33.33%)",
        "  Nausea 0/3 (0.00%)",
        "  Vomiting 0/3 (0.00%)",
        "  Fatigue 0/3 (0.00%)",
        "  Gait disturbance 0/3 (0.00%)",
        "  Oedema peripheral 0/3 (0.00%)",
        "  Pyrexia 0/3 (0.00%)",
        "Adverse Events 2:",
        "  Total: 4/5 (80.00%)",
        "  Anaemia 2/5 (40.00%)",
        "  Febrile neutropenia 0/5 (0.00%)",
        "  Leukopenia 0/5 (0.00%)",
        "  Sinus tachycardia 0/5 (0.00%)",
        "  Cataract 0/5 (0.00%)",
        "  Abdominal discomfort 0/5 (0.00%)",
        "  Diarrhoea 1/5 (20.00%)",
        "  Nausea 1/5 (20.00%)",
        "  Vomiting 1/5 (20.00%)",
        "  Fatigue 0/5 (0.00%)",
        "  Gait disturbance 0/5 (0.00%)",
        "  Oedema peripheral 0/5 (0.00%)",
        "  Pyrexia 1/5 (20.00%)"
    ]
}